Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;9(3):625-639.
doi: 10.1007/s40121-020-00322-5. Epub 2020 Jul 17.

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Johannes Beeslaar  1 , Paula Peyrani  2 , Judith Absalon  3 , Jason Maguire  3 , Joseph Eiden  3 , Paul Balmer  4 , Roger Maansson  2 , John L Perez  2
Affiliations

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Johannes Beeslaar et al. Infect Dis Ther. 2020 Sep.

Abstract

Introduction: An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults. Data were pooled from multiple studies within the program to examine whether MenB-FHbp immunogenicity was influenced by sex, age, or race.

Methods: Immunogenicity was assessed in subjects from seven studies who received 120 µg MenB-FHbp (at 0, 2, 6 months) and had evaluated immune responses against four representative test strains via serum bactericidal assays using human complement (hSBAs). Immune responses were presented by sex (male, female), age group (10-14, 15-18, 19-25, 10-25 years), and race (white, black, Asian, other).

Results: Among 8026 subjects aged 10-25 years included in this analysis, MenB-FHbp elicited robust immune responses in a high percentage of subjects regardless of demographic characteristics. Across all test strains and demographic subsets, a ≥ 4-fold rise in titer from baseline was achieved in 76.7-95.0% of subjects, with no major differences by sex, age groups assessed, or races evaluated. Corresponding percentages achieving titers ≥ the lower limit of quantification (LLOQ) against all four strains combined were 79.7-87.3% (sex), 81.6-85.5% (age), and 80.0-88.1% (race). Minor differences were observed for geometric mean titers and percentages of subjects achieving titers ≥ LLOQ against each strain based on demographics.

Conclusion: These data suggested no clinically meaningful differences in MenB-FHbp immunogenicity when administered as a three-dose schedule based on sex, ages assessed, or races evaluated. This analysis supports the continued recommended use of MenB-FHbp to prevent MenB disease in adolescents and young adults.

Trial registration: ClinicalTrials.gov identifiers, NCT00808028, NCT01830855, NCT01323270, NCT01461993, NCT01461980, NCT01352845, and NCT01299480.

Keywords: Clinical trial; Immunogenicity; Invasive meningococcal disease; Serogroup B; Vaccines.

PubMed Disclaimer

References

    1. Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12–S20. - PubMed
    1. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report (2017). https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf.
    1. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases (2019). https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases. Accessed 3 June 2019.
    1. Balmer P, York LJ. Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Ther Adv Vaccines Immunother. 2018;6:49–60. - PMC - PubMed
    1. Trumenba® (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc), Philadelphia; 2018.

Associated data

LinkOut - more resources